Kyverna Therapeutics is a clinical-stage biopharma company developing CAR T-cell therapies for autoimmune disease rather than cancer. Its lead approach aims for deep B-cell depletion and an immune-system “reset,” with the goal of durable, treatment-free remission in B-cell–driven conditions. Candidates such as mivocabtagene autoleucel (KYV-101) are being studied across serious autoimmune indications where current chronic therapies leave high unmet need.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -44.6 | — |
| Q2 2025 | 0 | — | -42.1 | — |
| Q3 2025 | 0 | — | -36.8 | — |
| Q4 2025 | 0 | — | -37.8 | — |
| Q1 2026 | 0 | — | -39.7 | — |
| Q2 2026 | 0 | — | -38.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Indaptus Therapeutics, Inc. (INDP), Fennec Pharmaceuticals Inc. (FENC), Vox Royalty Corp. (VOXR), Soren Acquisition Corp. (SORN), BlackRock TCP Capital Corp. (TCPC), Einride AB (ENRD)